CRANBURY, N.J. — Cornerstone Pharmaceuticals, Inc., a leader in the growing field of cancer metabolism-based therapeutics, today announced updated results from a Phase I clinical study of its first-in-class …
See more here:
Cornerstone Pharmaceuticals Presents Updated Phase I Data for CPI-613 at 2013 American Society of Hematology Annual …